3 Quantum Stocks Just Scored $100 Million in Government Funding. Which Is the Best to Buy Now?

The U.S. government awarded $100 million each to Rigetti, D-Wave and Quantinuum under the CHIPS Act to advance quantum computing, with Rigetti and D-Wave providing government equity stakes while Quantinuum did not. The article favors Quantinuum due to its trapped-ion accuracy, citing 99.92% two-qubit gate fidelity and a target of 99.999% logical fidelity for its Sol system next year. Rigetti leads on speed but trails materially on fidelity at 99.1%, while D-Wave is commercializing annealing systems and is still early in developing a gate-model platform.

Analysis

The key valuation distinction is not raw qubit speed but error-correction overhead: a sub-1 percentage-point improvement in two-qubit fidelity can reduce the physical-qubit and control-stack burden required for useful logical qubits by orders of magnitude. That makes the market likely to reward credible logical-fidelity milestones disproportionately over the next 1-3 months, while penalizing hardware roadmaps that require repeated capital raises before commercially relevant performance. RGTI and QBTS therefore retain meaningful dilution risk even if non-dilutive government support extends their runway.

QNT's relative advantage is potentially more important for the supply chain than for near-term quantum revenue. A qualified 300mm ion-trap production path would provide GFS with a high-value specialty-process reference customer, but the initial financial contribution is immaterial versus GFS's broader utilization and pricing cycle; treat it as strategic optionality rather than an earnings catalyst. HON benefits from retaining exposure to a potentially scarce quantum asset without bearing the same public-market volatility, making it a cleaner lower-beta expression if Quantinuum's listing, float, and government-funding terms are not independently verified.

Consensus may be underestimating that the government equity component can create a financing signal rather than a pure subsidy: it validates strategic relevance but establishes a new stakeholder whose exit restrictions, governance rights, and anti-dilution provisions could cap upside for public shareholders. The first tradable catalyst is disclosure of award timing, equity terms, and milestone-based disbursement; the 6-18 month determinant is whether claimed logical-fidelity progress translates into customer workloads and recurring software/services revenue rather than benchmark headlines. A sustained improvement in IONQ's commercial bookings or technical metrics would weaken the relative-QNT thesis by offering investors a more liquid accuracy-oriented alternative.

Key Decisions for Investors

• Do not chase QBTS or RGTI on the funding narrative alone; wait for disclosed dilution, warrant, and governance terms. Consider tactical shorts only after a post-news rally if financing documents imply material fully diluted share-count expansion; cover on confirmed non-dilutive tranches or a verified technical milestone.
• Subject to verification that QNT is a liquid, investable listed security, establish a 3-6 month relative long QNT / short equal-beta QBTS and RGTI basket. The thesis is that error-correction credibility should command a premium; invalidate if QNT misses its next logical-fidelity target, reports weak commercial conversion, or QBTS/RGTI disclose a materially superior fidelity roadmap.
• For a lower-volatility 6-18 month expression, accumulate HON rather than treating quantum exposure as a standalone earnings driver. Size it as an industrial/automation position with quantum optionality; reassess if ownership economics are diluted, monetization is separated on unfavorable terms, or core HON guidance deteriorates.
• Keep GFS on watch rather than buying for this headline. Upgrade only if management identifies quantum or adjacent photonics/specialty wafer demand as a measurable utilization contributor; the relevant confirmation is incremental wafer-volume guidance, not an announced development partnership.